SAMe for depression
This article was originally published in The Tan Sheet
Executive Summary
Augmentation of antidepressant therapy with S-adenosyl-L-methionine (SAMe) "warrants a placebo-controlled trial in resistant depression," authors of a Pharmavite-sponsored trial conclude in the Dec. 6 Journal of Clinical Psychopharmacology. Jonathan Alpert, MD/PhD, Massachusetts General Hospital, et al., administered 800 to 1,600 mg of SAMe to antidepressant partial and non-responders over a six-week period, recording a 50% response rate and a 43% rate of remission. A double-blind, placebo-controlled study at NIH to test SAMe as an adjunct antidepressant therapy also is being conducted by Alpert et al. A second NIH study will test SAMe against standard antidepressants and placebo...